Flash Glucose Monitoring and Patient Satisfaction: A Meta-Review of Systematic Reviews

Ana Díez-Fernández, María Dolores Rodríguez-Huerta, Rubén Mirón-González, José Alberto Laredo-Aguilera and Noelia María Martín-Espinosa
Additional contact information
Ana Díez-Fernández: Centro de Estudios Sociosanitarios, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain
María Dolores Rodríguez-Huerta: Intensive Care Unit, La princesa University Hospital, 28006 Madrid, Spain
Rubén Mirón-González: Community Care and Social Determinants of Health Research Group, Department of Nursing and Physiotherapy, University of Alcalá de Henares, 28805 Alcalá de Henares, Spain
José Alberto Laredo-Aguilera: Departamento de Enfermería, Fisioterapia y Terapia ocupacional, Universidad de Castilla-La Mancha, Campus Universitario s/n, 02071 Albacete, Spain
Noelia María Martín-Espinosa: Community Care and Social Determinants of Health Research Group, Department of Nursing and Physiotherapy, University of Alcalá de Henares, 28805 Alcalá de Henares, Spain

IJERPH, 2021, vol. 18, issue 6, 1-13

Abstract: Flash glucose monitoring (FGM) systems have been suggested to have clinical beneficial effects in patients with diabetes mellitus, although their improvements in terms of quality of life (QoL) and patients’ satisfaction are not always addressed or are considered a secondary outcome. Thus, the aim of this meta-review is to establish the benefits of FGM in terms of patients’ satisfaction and QoL in both type 1 and type 2 diabetes patients using evidence from past systematic reviews and meta-analyses. Major databases were searched for systematic reviews (with or without meta-analyses) that assessed the satisfaction or QoL of type 1 or 2 diabetes patients using FGM compared with other glucose monitoring systems. The quality of the included systematic reviews was addressed with the Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) tool. Six systematic reviews (including two meta-analyses) were included in the meta-review. Evidence suggests that FGM systems seem to improve patients’ satisfaction and QoL compared with self-monitoring of blood glucose, although the high variability in the measurement tools, the clinical significance and the quality of the systematic reviews included do not allow us to state FGM benefits with any certainty. Further research, including high-quality randomised clinical trials, differentiating the needs of both type 1 and type 2 diabetes patients and focusing on psychosocial benefits for these patients is needed to optimise clinical decisions between patients and professionals by developing the right health technology assessment for FGM systems.

Keywords: flash glucose monitoring; quality of life; patients’ satisfaction; diabetes mellitus; meta-review (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/6/3123/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/6/3123/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:6:p:3123-:d:519464

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().